3.Neu H.C. the Development of Macrolides: Clarithromycin in Perspective. J Antimicrob Chemother

Литературак статье «Кларитромицин: есть ли потенциал для клинического использования в XXI веке?» (С.А. Рачина, Л.С. Страчунский, Р.С. Козлов)

1.Forrest G.N., Oldach D.W. Macrolides and clindamycin. In: Gorbach S.L., Bartlett J.G., Blacklow N.R., editors. Infectious Diseases. Lippincott Williams and Wilkins, 3d edition, 2004, 213-33.

2.Bryskier A. and Butzler J.-P. Macrolides. In: Finch R.G., Greenwood D., Norrby S.R., Whitley R.J., editors. Antibiotic and Chemotherapy. Anti-infective agents and their use in therapy. Churchill Livingstone, 8th edition, 2003, p. 310-25.

3.Neu H.C. The development of macrolides: clarithromycin in perspective. J Antimicrob Chemother 1991; 27 (Suppl A):1-9.

4.McCaig L.F., Besser R.E., Hughes J.M. Antimicrobial drug prescription in ambulatory care settings, United States, 1992-2000. Emerg Infect Dis 2003; 9(4):432-437.

5.Mazzei T., Mini E., Novelli A., Periti P. Che­mi­­stry and mode of action of macrolides. J Anti­microb Chemother 1993; 31 (Suppl C):1-9.

6.C.J. Carbon, E. Rubinstein. Macrolides, ketolides, lincosamides and streptogramins. In: J. Cohen, W.G. Powderly, S.M. Opal, S.F. Berkley, T. Calandra, N. Clumeck, e.a., editors. Infectious Diseases. Elsevier Limited, 2nd edition, 2004, p. 1791-1803.

7.S. Sivapalasingam, N.H. Steigbigel. Macrolides, clindamycin, and ketolides. In: G.L. Mandell, J.E. Bennett, R. Dolin, editors. Pronciples & Practice of Infectious Diseases. Churchill Livingstone, 6th edition, 2004, p. 396-417.

8.Bergeron MG, Bemier M, L‘Ecuyer J. In vitro activity of clar­ithromycin and its 14-hydroxy-metabolite against 203 strains of Haemophilus influenzae. Infection 1992; 20:164-167.

9.Malanoski G.J., Eliopoulos G.M., Ferraro M.J., Moellering R.C. Jr. Effect of pH variation on the susceptibility of Helicobacter pylori to three macrolide antimicrobial agents and temafloxacin. Eur J Clin Microbiol Infect Dis. 1993; 12:131-3.

10.Loo V.G., Fallone C.A., De Souza E., Lavallee J., Barkun A.N. In-vitro susceptibility of Helicobacter pylori to ampicillin, clarithromycin, metronidazole and omeprazole. J Antimicrob Chemother 1997; 40:881-883.

11.Doucet-Populaire F., Capobianco J.O., Zakula D., Jarlier V., Goldman R.C. Molecular basis of clarithromycin activity against Mycobacterium avium and Mycobacterium smegmatis. J Antimicrob Chemother 1998; 41:179-187.

12.Doucet-Populaire F., Buriankova K., Weiser J., Pernodet J.L. Natural and acquired macrolide resistance in mycobacteria. Curr Drug Targets Infect Disord 2002; 2:355-370.

13.Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis 2002; 34:482-492.

14.Edelstein P.H. Pneumococcal resistance to macrolides, lincosamides, ketolides, and streptogramin B agents: molecular mechanisms and resistance phenotypes.
Clin Infect Dis 2004; 38 (Suppl 4):S322-327.

15.Bingen E., Leclercq R., Fitoussi F., Brahimi N., Malbruny B., Deforche D., Cohen R. Emergence of group A Streptococcus strains with different mechanisms of macrolide resistance. Antimicrob Agents Chemother 2002; 46:1199-1203.

16.Megraud F. Basis for the management of drug-resistant Helicobacter pylori infection. Drugs 2004; 64:1893-1904.

17.Kozlov R.S., Bogdanovitch T.M., Appelbaum P.C., Ednie L., Stratchounski L.S., Jacobs M.R., Bozdogan B. Antistreptococcal activity of telithromycin compared with seven other drugs in relation to macrolide resistance mechanisms in Russia. Antimicrob Agents Chemother 2002; 46:2963-2968.

18.Matsuoka M., Sasaki T. Inactivation of macrolides by producers and pathogens. Curr Drug Targets Infect Disord 2004; 4:217-240.

19. Rodvold KA. Clinical pharmacokinetics of clarithromycin. Clin Pharmacokinet 1999; 37:385-398.

20. Abbott Laboratories. Biaxin® Prescribing Information. Available from

21.Chu S., Deaton R., Cavanaugh J. Absolute bioavailability of clarithromycin after oral administration in humans. Antimicrob Agents Chemother 1992; 36:1147-1150.

22.Guay D.R.P., Gustavson L.E., Devcich K.J., Zhang J., Cao G., Olson CA. Pharmaco-kinetics and tolerability of extended-release clarithromycin. Clin Ther 2001: 23:566-577.

23.Gotfried M.H. Clarithromycin (Biaxin) extended-release tablet: a therapeutic review.
Expert Rev Anti Infect Ther 2003; 1:9-20.

24.Bearden DT, Rodvold KA. Practical pharmacology - penetration of macrolides into pulmonary sites of infection. Infect Med 1999; 16:480A-484A.

25.Rodvold K.A., Gotfried M.H., Danziger L.H., Sorvi R.J. Intrapulmonary steady-stale concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob Agents Chemother 1997; 41:1399-1402.

26.Fish D.N., Gotfried M.H., Danziger L.H., Rodvold K.A. Penetration of clarithromycin into lung tissues from patients undergoing lung resection. Antimicrob Agents Chemother 1994; 38:876-888.

27.Gotfried M.H., Danziger L.H., Rodvold K.A. Steady-state plasma and bronchopulmonary characteristics of clarithromycin extended-release tablets in normal healthy adult subjects.JAC 2003; 52:450-456.

28.Fietta A., Merlini C., Gialdroni Grassi G. Requirements for intracellular accumulation and release of clarithromycin and azithromycin by human phagocytes. J Chemother 1997; 9:23-31.

29.Kees F, Wellenhofer M, Grobecker H. Serum and cellular pharmacokinetics of clarithro-mycin 500 mg q.d. and 250 mg b.i.d. in volunteers. Infection 1995; 23:168-172.

30.Craft J.C., Siepman N. Overview of the safety profile of clar­ithromycin suspension in pediatric patients. Pediatr Infect Dis J 1993; 12 (Suppl 3):S142-147.

31.Guay D.R., Patterson D.R., Seipman N., Craft J.C. Overview of the tolerability profile of clarithromycin in preclinical and clinical trials. Drug Saf 1993; 8:350-364.

32.Kolkman W., Groeneveld J.H., Baur H.J., Verschuur H.P. Ototoxicily induced by clarithromycin. Ned Tijdschr Geneeskd. 2002; 146:1743-1745.

33.Roussel G., Igual J. Clarithromycin with minocycline and clofazimine for Mycobacterium avium intracellulare complex lung disease in patients without the acquired immune deficiency syndrome. GETIM. Groupe d’Etude et de Traitement des Infections a Mycobacteries. Int J Tuberc Lung Dis 1998; 2:462-470.

34.Gomez­Gil E., Garcia F., Pintor L., Martinez J.A., Men­sa J., de Pablo J. Clarithromycin-induced acute psychoses in peptic ulcer disease. Eur J Clin Microbiol Infect Dis 1999; 18:70-71.

35.Prime K., French P. Neuropsychiatric reaction induced by clarithromycin in a patient on highly active antiretroviral therapy (HAART). Sex Transm Infect 2001; 77:297-298.

36.de Dios Garcia-Diaz J., Santolaya Perrin R., Paz Martinez Ortega M., Moreno-Vazquez M. Phlebitis due to intravenous administration of macrolide antibiotics. A comparative study of erythromycin versus clarithromycin. Med Clin 2001;116:133-5.

37.Fogarty C., Grossman С., Williams J., Haverstock D., Church D. Efficacy and safety of moxifloxacin vs. clarithromycin for community-acquired pneumonia. Inf Med 1999; 16:748-763.

38.Ramirez J., Unowsky J., Talbot G.H., Zhang H., Town­send L. Sparfloxacin vs. clarithromycin in the treatment of community-acquired pneumonia. Clin Ther 1999; 21:103-116.

39.McCarty J.M., Pierce P.F. Five days of cefprozil versus 10 days of clarithromycin in the treatment of an acute exacerbation of chronic bronchitis. Ann Allergy Asthma Immunol 2001; 87:327-334.

40.Lode H., Eller J., Linnhoff A., Ioanas M.; Evaluation of Therapy­Free Interval in COPD Patients Study Group.Levofloxacin versus clarithromycin in COPD exacerbation: focus on exacerbation-free interval. Eur Respir J 2004; 24:947-953.

41.McCarty J., Hedrick J.A., Gooch W.M. Clarithromycin suspension vs penicillin V suspension in children with streptococcal pharyngitis. Adv Ther 2000; 17:14-26.

42.Devcich K., Busman T., Olson C., Notario G. Adverse event severity comparisons with extended-release clarithromycin and immediate-release clarithromycin. In: Proceedings of the Program and Abstracts of the 40th Annual Meeting of the Infectious Diseases Society of America, Chicago, IL, 24-27 October 2002 [abstract 212].

43.Westphal J.F. Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithro­­mycin, azithromycin and dirithro­mycin.
Br J Clin Pharmacol 2000; 50:285-295.

44.Gustavson L.E., Kaiser J.F., Edmonds A.L., Locke C.S., DeBartolo M.L., Schneck D.W. Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob Agents Chemother 1995; 39:2078-2083.

45.Saito M., Yasui­Furukori N., Uno T., Takahata T., Suga­wara K., Munakata A., Tateishi T. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. Br J Clin Pharmacol 2005; 59:302-309.

46.Berning S.E., Peloquin C.A. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Clin Infect Dis 1996; 22:885.

47.Polis M.A., Piscitelli S.C., Vogel S., Witebsky F.G., Conville P.S., Petty B., et al. Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infection. Antimicrob Agents Chemother 1997; 41:1709-1714.

48.R. Van Heeswijk, J. Sabo, T. Macgregor, M. Elgadi, F. Harris, S. Mccallister, D.Mayers. The effect of tipranavir/ritonavir 500/200 mg bid on the pharmacokinetics of clarithromycin in healthy volunteers. In: Abstracts of the 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 14-17 September 2004 [abstract 457].

49.Hung I.F., Wu A.K., Cheng V.C., Tang B.S., To K.W., Yeung C.K., et al. Fatal interaction between clarithromycin and colchicines in patients with renal insufficiency: a retrospective study. Clin Infect Dis 2005; 41:291-300.

50.P.C. Woo, S.K. Lau, K.-Y. Yuen. Macrolides as immunomodulatory agents. Curr Med Chem - Anti-Inflammatory & Anti-Allergy Agents 2002; 1:131-141.

51.Culic O. Erakovic V. Pamham M.J. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 2001; 429:209-229.

52.Labro M.T., Abdelghaffar H. Immunomodulation by macrolide antibiotics. Journal of Chemotherapy 2001; 13:3-8.

53.Tamaoki J. The effects of macrolides on inflammatory cells. Chest 2004; 125:41S-51S.

54.Demartini G., Esposti D., Marthyn P., Lapidari A., Fra­schi­ni F., Scaglione F. Effect of multiple doses of clarithromycin and amoxicillin on IL-6, IFNgamma and IL-10 plasma levels in patients with community acquired pneumonia. J Chemother 2004; 16:82-85.

55.Tamaoki J., Takeyama K., Tagaya E., Konno K. Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections.
Antimicrob Agents Chemother 1995; 39:1688-1690.

56..Tagaya E., Tamaoki J., Kondo M., Nagai A. Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion.
Chest 2002; 122:213-218.

57.Rubin B.K., Druce H., Ramirez O.E., Palmer R. Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis. Am J Respir Crit Care Med 1997; 155:2018-2023.

58.Molinari G., Guzman C.A., Pesce A., Schito G.C. Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics. J Antimicrob Chemother 1993; 31:681-688.

59.Kawamura­Sato K., Iinuma Y., Hasegawa T., Yamashino T., Ohta M. Postantibiotic suppression effect of macrolides on the expression of flagellin in Pseudomonas aeruginosa and Proteus mirabilis. J Infect Chemother 2001; 7:51-54.

60.Lagrou K., Peetermans W.E., Jorissen M., Verhaegen J., Van Damme J., Van Eldere J. Subinhibitory concentrations of erythromycin reduce pneumococcal adherence to respiratory epithelial cells in vitro. J Antimicrob Chemother 2000; 46:717-723.

61.D.J. Wozniak and R. Keyser. Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa. Chest 2004; 125: 62S-69S.

62.Jacobs M.R., Felmingham D., Appelbaum P.C., Gruneberg R.N.; The Alexander Project Group. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infections to commonly used antimicrobial agents J Antimicrob Chemother 2003; 52:229-246.

63.Mera R.M., Miller L.A., Daniels J.J., Weil J.G., Whi­te A.R. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States over a 10-year period: Alexander Project. Diagn Microbiol Infect Dis 2005; 51:195-200.

64.Heilmann S., Beekmann S., Richter S., Garcia-de Lovias J., Doern G.. Antimicrobial resistance with Streptococcus pneumoniae in 2003 – results of the multinational GRASP surveillance program. In: Abstracts of the 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, Chech Respublic, 1-4 May 2004 [abstract P1130].

65.Hiramatsu K., Ohama M., Mijajima Y., Kishi K., Mizunoe S., TokimatsuI., et al. Antimicrobial susceptibilities and analysis of genes related to penicillin or macrolide resistance in Streptococcus pneumoniae. Int J Antimicrob Agents. 2004; 24:125-129.

66.Kozlov R.S.,Sivaja O.V.,Stratchounski L.S.7-years monitoring of resistance of clinical S.pneumoniae in Russia: results of prospective multicenter study (PEHASus). Proceedings of 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 2005 Dec 16-19; WashingtonDC

67.Козлов Р.С. Пути оптимизации мониторинга, профилактики и фармакотерапии пневмококковых инфекций: Автореф. дис. д-ра мед. наук. - Смоленск, 2004. - 46 с.

68.Farrell D.J., MorrisseyI., Bakker S., Felmingham D. Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study. J Antimicrob Chemother 2002; 50 (Suppl S1):39-47.

69.Farrell D.J., Jenkins S.G. Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with respiratory tract infections: PROTEKT US 2001-2002. J Antimicrob Chemother 2004; 54 (Suppl 1):i17-22.

70.R.J. Davidson, C.C.K.Chan, G. Doern, G.G. Zhanel. Macrolide-resistant Streptococcus pneumoniae in Canada: correlation with azithromycin use. In: Abstracts of the 13th European Congress of Clinical Microbiology and Infectious Diseases, Glasgow, UK, 10-13 May 2003 [abstract P1031].

71.Aspa J., Rajas O., Rodriguez de Castro F., e. a. Drug-resistant pneumococcal pneumonia: clinical relevance and related factors. Clin Infect Dis 2004; 38:787-798.

72.Lynch III J.P., Martinez F.J.. Clinical revalence of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia. Clin Infect Dis 2002; 34 (Suppl 1):S27-46.

73.Kays M.B., Denys G.A. In vitro activity and pharmacodynamics of azithromycin and clarithromycin against Streptococcus pneumoniae based on serum and intrapulmonary pharmacokinetics. Clin Ther 2001 Mar; 23:413-424.

74.Noreddin A.M., Roberts D., Nichol K., Wierzbowski A., Hoban D.J., Zhanel G.G. Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free-drug concentrations. Antimicrob Agents Chemother 2002; 46:4029-4034.

75.Horvat T., Warkentine F., Li Y.. Bactericidal activity and postantibiotic effects of clarithromycin against Streptococcus pneumoniae with the efflux mechanism of macrolide resistance. In: Abstracts of the 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, Chech Respublic, 1-4 May 2004 [abstract P1820].

76.Stein G.E., Schooley S. Comparative serum bactericidal activity of clarithromyein and azithromycin against macrolide-sensitive and resistant strains of Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2001; 39:181-185.

77.Kaplan E.L., Johnson D.R., Del Rosario M.C., Horn D.L. Susceptibility of group A beta-hemolytic streptococci to thirteen antibiotics: examination of 301 strains isolated in the United States between 1994 and 1997. Pediatr Infect Dis J 1999; 18:1069-1072.

78.Canton R., Loza E., MorosiniI., Baquero F. Antimicrobial resistance amongst isolates of Streptococcus pyogenes and Slaphylococcus aureus in the PROTEKT antimicrobial surveillance programme during 1999-2000. J Antimicrob Chemother 2002; 50(Suppl Sl):9-24.

79.Richter S.S., Heilmann K.P., Beekmann S.E., Miller N.J., Miller A.L., Rice C.L., et al. Macrolide-resistant Streptococcus pyogenes in the United States, 2002-2003.
Clin Infect Dis 2005; 41:599-608.

80.Kataja J., Huovinen P., Skurnik M., Seppala H. Erythromycin resistance genes in group A streptococci in Finland. The Finnish Study Group for Antimicrobial Resistance. Antimicrob Agents Chemother 1999; 43:48-52.

81.Ho P.L., Johnson D.R., Yue A.W., Tsang D.N., Que T.L., Beall B., Kaplan E.L. Epidemiologic analysis of invasive and noninvasive group a streptococcal isolates in Hong Kong. J Clin Microbiol 2003; 41:937-942.

82.Sivaja O., Kozlov R.S., Stratchounski L.S., PEHASus project group. Current state of antimicrobial resistance of S.pyogenes (GAS) in Russia: results of prospective multicentre study (PEHASus-I, PHASE “B”). Proceedings of the 1st FEMS Congress of European Microbiologists. Ljubljana, Slovenia; June 29-July 3, 2003. P. 235.

83.Sauermann R., Gattringer R., Graninger W., Bux­ba­umA., Ge­orgopoulos A. Phenotypes of macrolide resistance of group A streptococci isolated from outpatients in Bavaria and susceptibility to 16 antibiotics. J Antimicrob Chemother 2003; 51:53-57.

84.Gattringer R., Sauermann R., Lagler H., Stich K., Buxbaum A., Graninger W., Georgopoulos A. Anti­microbial susceptibility and macrolide resistance genes in Streptococcus pyogenes collected in Austria and Hungary. Int J Antimicrob Agents 2004; 24:290-293.

85.Страчунский Л.С., Богданович Т.М. Состояние резистентности к антиинфекционным химиопрепаратам в России. Практическое руководство по антиинфекционной химиотерапии. Под ред. Страчунского Л.С., Белоусова Ю.Б., Козлова С.Н. - М.: Боргес, 2002. - С. 32-39.

86.Varaldo P.E., Debbia E.A., Nicoletti G., Pavesio D., Ripa S., Schito G.C., Tempera G. Nationwide survey in Italy of treatment of Streptococcus pyogenes pharyngitis in children: influence of macrolide resistance on clinical and microbiological outcomes. Artemis-Italy Study Group. CID 1999; 29:869-873.

87.Bassetti M., Manno G., Collida A., Ferrando A., Gatti G., Ugolotti E., et al. Erythromycin resistance in Streptococcus pyogenes in Italy. Emerg Infect Dis 2000; 6: 180-183.

88.Bergeron M.G., Bemier M., L’Ecuyer J. In vitro activity of clar­ithromycin and its 14-hydroxy-metabolite against 203 strains of Haemophilus influenzae. Infection 1992; 20: 164-167.

89.Fass R.J. Erythromycin, clarithromycin, and azithromycin: use of frequency distribution curves, scattergrams, and regression analyses to compare in vitro activities and describe cross-resistance. Antimicrob Agents Chemother 1993, 37: 2080-2086.

90.Thomsberry C., Sahm D.F., Kelly L.J., et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella caiarrhalis in the United States: results from the TRUST surveillance program, 1999-2000. Clin Infect Dis 2002; 34 (Suppl 1): S4-S16.

91.Critchley I.A, Jones M.E., Heinze P.D., Hubbard D., Engler H.D., Evangelista A.T, e.a.. In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneu-mophila, Mycoplasma pneumoniae, and Chlamydia pneumoniae from North America and Europe. Clin Microbiol Infect 2002; 8:214-221.

92.Helicobacter pylori: Review and update. Hospital Physician. May 2002, p. 23-31.

93.Malfertheiner P., Megraud F., O’Morain C., Hungin A.P., e.a.; European Helicobacter Pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection - The Maastricht 2-2000 Consensus Report. Aliment Fharmacol Ther 2002; 16:167-180.

94.Meurer L.N., Bower D.J. Management of Helicobacter pylori infection. Am Fam Physician 2002; 65:1327-1336.

95.Megraud F. Basis for the management of drug-resistant Helicobacter pylori infection.
Drugs 2004; 64:1893-1904.

96.Glupczynski Y., Megraud F., Lopez-Brea M., Andersen L.P. European multicenter survey of in vitro antimicrobial resistance in Helicobacler pylori. Eur J Clin Microbiol Infecl Dis 2000; 11:820-823.

97.Crone J., Granditsch G., Huber W.D., Binder C., Innerhofer A., Amann G., Hirschl A.M. Helicobacler pylori in children and adolescents: increase of primary clarithromycin resistance, 1997-2000. J Pediatr Gaslroenterol Nutr 2003; 36:368 371.

98.Bontems P., Devaster J.M., Corvaglia L., Dezsofi A., Van Den Borre C., Goutier S., et al. Twelve year observation of primary and secondary antibiotic resistant Helicobocter pylori strains in children. Pediatr Infect Dis J 2001; 20:1033-1038.

99.Boyanova L., Koumanova R., Gergova G., Popova M., Mitov I., Kovacheva Y., et al. Prevalence of resistant Helicobocter pylori isolates in Bulgarian children. J Med Microbiol 2002; 51:786-790.

100. Dzierzanowska­Fangrat K., Rozynek E., Jozwiak P., Celinska­Cedro D., Madalinski K., Dzierzanowska D. Primary resistance to clarilhromycin in clinical strains of Helicobacter pylori isolated from children in Poland. Inf J Aniimicrob Agents 2001; 18:387 -390.

101. Boyanova L., Mentis A., Gubina M., Rozynek E., Gosciniak G., Kalenic S., et al. The status of antimicrobial resistance of Helicobacter pylori in Eastern Europe. Clin Microbiol Infect 2002; 8:388-396.

102. Л.В. Кудрявцева, П.Л. Щербаков, И.О. Иваников,В.М. Говорун.Helicobacter pylori-инфекция: современные аспекты диагностики и терапии. Пособие для врачей - М.; 2004.

103. Megraud F. H.pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53:1374-1384.

104. Houben M.H., van de Beek D., Hensen E.F., Cra­en A. J., Rauws E.A., Tytgat G.N. A systematic review of Helicobacter pylori eradication therapy - the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 1999; 3:1047-1055.

105. McMahon B.J., Hennessy T.W., Bensler J.M., Bruden D.L., Parkinson A.J., Morris J.M., et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med 2003; 139:463-469.

106. Cuchi Burgos E., Forne Bardera M., Quintana Riera S., Lite Lite J., Garau Alemany J. Evolution of the sensitivity of 235 strains of Helicobocler pylori from 1995 to 1998 and impact of antibiotic treatment Enferm Infecc Microbiol Clin 2002; 20:157-160.

107. Duck W.M., Sobel J., Pruckler J.M., Song Q., Swerdlow D., Friedman C., et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis 2004; 10:1088-1094.

108. Gilbert K., Gleason P.P., Singer D.E., Marrie T.J., Coley C.M., Obrosky D.S., et al. Variations in antimicrobial use and cost in more than 2,000 patients with community-acquired pneumonia. Am J Med 1998; 104:17-27.

109. Marrie T.J., Lau C.Y., Wheeler S.L., Wong C.J., Vandervoort M.K., Feagan B.G. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Commu­nity-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 2000; 283:749-755.

110. Ewig S., Ruiz M., Torres A., Marco F., Martinez J.A., Sanchez M., Mensa J. Pneumonia acquired in the community through drug-resistant S. pneumoniae. Am J Respir Crit Care Med 1999; 159:1835-1842.

111. Kelley M., Weber D.J., Gilligan P., Cohen M.S. Breakthrough pneumococcal bacteremia in patients being treated with azithromyein and clarithromycin. Clin Infect Dis 2000; 31:1008-1011.

112. Lonks J., Garau J., Gomez L., Xercavins M., Ochoa de Echaguen A., Gareen I.F., e. a. Failure of macrolide antibiotic in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002; 35:556-564.

113. Rzeszutek M., Wierzbowski A., Hoban D., Conly J., Bishai W., Zhanel G.G. A review of clinical failures associated with macrolide-resistant Streptococcus pneumoniae. Internat J Antimicrob Agents 2004; 24: 95-104.

114. Niederman M.S., Mandell L.A., Anzueto A., Bass J.B., Broughton W.A., Campbell G.D., et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention. Am J Respir Crit Care Med 2001; 163:1730-1754.

115. Mandell L.A., Marrie T.J., Grossman R.F., et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000; 31:383-421.

116. Mandell L.A., Bartlett J.G., Dowell S.F., File T.M., Jr., Musher D.M., Whitney C.. Update of Practice Guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37:1405-1433.

117. ЧучалинА.Г., СинопальниковА.И., ЯковлевС.В., СтрачунскийЛ.С., КозловР.С., РачинаС.А.. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике. Пособиедляврачей. 2003.

118. File T., Garau J., Blasi F., Chidiac C., Klugman K., Lode H., e. a. Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia. Chest 2004; 125: 1888-1901.

119. Thibodeau K.P., Viera A.J.. Atypical pathogens and challenges in community-acquired pneumonia. Am Fam Physician 2004; 69:1699-1706.

120. Roig J., Sabria M., Alegre J., Gurdui M., Checa J.C. Spanish Study Group for Legionella. Comparative randomized open multicentre trial assessing the efficacy and safety of intravenous/oral azithromycin compared with intravenous/oral clarithromycin for the treatment of community-acquired pneumonia due to Legionella pneumophila. In: Abstracts of the 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, Chech Respublic, 1-4 May 2004 [abstract P433].